SCHEMBL6281909

SCHEMBL6281909

COc1ccc(CC(=O)OCc2ccccc2)cc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2C19 P33261 1/20 0.64
ALDH1A1 P00352 4/20 0.63
MAPK1 P28482 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
KMT2A Q03164 2/20 0.60
ALOX5 P09917 1/20 0.56
POLB P06746 2/20 0.54
LMNA P02545 2/20 0.53
PPARG P37231 1/20 0.53
PPARA Q07869 1/20 0.53
GAA P10253 4/20 0.52
MAPT P10636 3/20 0.52
MEN1 O00255 1/20 0.52
HPGD P15428 1/20 0.52
BCHE P06276 2/20 0.52
ACHE P22303 2/20 0.52
LDHA P00338 1/20 0.51
ABL1 P00519 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6366353 0.93 NPC1 (0.59) CYP1A2CYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL11000898 0.91 GAA (0.57) CYP1A2CYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL14768424 0.90 ALDH1A1 (0.61) CYP1A2CYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL6081043 0.89 ALDH1A1 (0.64) CYP1A2CYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL5151754 0.87 ALDH1A1 (0.58) CYP1A2CYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL31530756 0.87 ALDH1A1 (0.58) CYP1A2CYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL5795000 0.87 ALDH1A1 (0.51) CYP1A2CYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL24296561 0.85 L3MBTL1 (0.63) ALDH1A1MAPK1L3MBTL1KMT2AALOX5
SCHEMBL9724394 0.85 APP (0.62) CYP1A2CYP3A4CYP2C19KMT2AMEN1
SCHEMBL9416619 0.85 APP (0.56) CYP1A2CYP3A4CYP2C19ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852713-B2 Lactam derivatives and methods of their use ADOLOR CORPORATION (US) 2005-02-08 US disclosed
WO-2004093796-A2 LACTAM DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2004-11-04 WO disclosed
US-20040209857-A1 Lactam derivatives and methods of their use ADOLOR CORPORATION 2004-10-21 US disclosed
US-6207686-B1 FOR THERAPY OF HYPERTENSION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-27 US disclosed
EP-0792265-A1 ENDOTHELIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-09-03 EP disclosed
WO-1996015109-A1 ENDOTHELIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209857-A1 Lactam derivatives and methods of their use MRPL21, SI, PEPD CYP1A2 100/4885CYP3A4 93/4885CYP2C19 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.